乾癬藥物市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按治療類型、作用機制、給藥途徑、地區、競爭細分

2022年，全球乾癬藥物市場估值達210.6億美元，預計在未來一段時間內大幅成長，預計到2028年年複合成長率（CAGR）為6.57%。全球乾癬藥物市場代表製藥業中一個充滿活力且快速發展的部門，主要是由於銀屑病患病率不斷上升、治療方案的進步以及對更有效的治療干涉措施的需求不斷成長而推動的。本市場概述提供了對現狀以及塑造全球銀屑病藥物市場的關鍵因素的見解。

主要市場促進因素

市場概況
預測期	2024-2028
2022 年市場規模	210.6億美元
2028 年市場規模	307.9億美元
2023-2028 年年複合成長率	6.57%
成長最快的細分市場	口服
最大的市場	北美洲

牛皮癬盛行率增加

牛皮癬盛行率的增加是指全世界被診斷出患有這種慢性自體免疫性皮膚病的人數不斷增加。牛皮癬的特徵是皮膚細胞快速積聚，導致脫皮、發紅和發炎等症狀。牛皮癬有遺傳因素，有家族病史的人更有可能患上牛皮癬。隨著家庭的擴大和遺傳訊息的傳承，牛皮癬病例的可能性增加。

環境觸發因素，例如壓力、吸煙和某些感染，可能會加劇牛皮癬或引發其發作。在我們的現代生活方式中，接觸這些觸發因素變得越來越普遍，導致盛行率不斷增加。飲食習慣的改變、久坐的生活方式以及接觸污染和城市環境的增加可能會影響牛皮癬的發展。這些生活方式因素會影響免疫系統和皮膚健康，可能導致牛皮癬。醫學知識和診斷技術的進步使牛皮癬病例得到了更好的識別和診斷。醫療保健提供者現在更善於識別這種疾病，即使是較輕微的形式，這導致盛行率明顯上升。

研究與開發的進步

製藥業的研發 (R&D) 工作取得了顯著進步，特別是在皮膚病學和自體免疫疾病領域。這些進步包括對銀屑病分子機制的更深入了解、新藥物標靶的發現以及更有針對性和更有效的療法的開發。研發的進步對於推動市場成長至關重要，因為它們可以創造出更好的牛皮癬藥物。這些創新提高了藥物的療效、減少了副作用並改善了患者的治療效果。創新療法的承諾鼓勵了對牛皮癬藥物市場的投資，吸引了製藥公司和投資者。

不斷變化的監管環境

負責藥品核准的監管機構已經適應了不斷變化的醫療保健環境。他們認知到迫切需要安全有效的牛皮癬治療方法。因此，批准牛皮癬藥物的監管程序變得更加高效和寬鬆。不斷發展的監管環境對於市場成長至關重要，因為它加快了新的牛皮癬藥物上市所需的時間。簡化核准意味著製藥公司可以更快地將其產品商業化，從而更迅速地滿足患者的需求並保持市場競爭力。

提高患者意識

如今，患者可以更多地獲取有關牛皮癬及其可用治療方法的資訊。這主要歸功於網路、病患權益團體和醫療保健教育措施。患者越來越主動地尋求治療方案並倡導他們的醫療保健需求。患者意識的提高是市場成長的重要推動力，因為知情的患者更有可能為牛皮癬尋求醫療協助。他們積極與醫療保健提供者合作，從而實現更早的診斷和治療。這一趨勢不僅使患者受益，也刺激了對牛皮癬藥物的需求。

主要市場挑戰

對牛皮癬原因和觸發因素的了解有限

牛皮癬是一種多因素自體免疫疾病，其確切原因仍不清楚。其病理生理學的複雜性使得開發標靶療法具有挑戰性。牛皮癬發作可能由多種因素引發或加劇，包括壓力、感染和生活方式的選擇。單獨理解和解決這些觸發因素是一項複雜的任務。

遺傳傾向在銀屑病中發揮作用，但涉及的遺傳因素是多種多樣的。根據特定基因譜量身訂做治療方法是限制個人化治療發展的挑戰。

研發成本高

開發新的牛皮癬藥物需要進行廣泛的臨床試驗以確保安全性和有效性。這些試驗成本高昂且耗時，通常需要數年時間才能完成。

滿足藥品（包括牛皮癬治療）的嚴格監管要求需要大量的財務投資。這可能會阻止規模較小的製藥公司進入市場。製藥業的競爭本質意味著公司需要在研發方面進行大量投資才能保持領先地位。這種高水準的競爭可能對小公司構成障礙。

獲得治療和醫療保健的差距

一些針對牛皮癬的新型生物療法可能非常昂貴，限制了沒有全面保險範圍的個人的使用。負擔能力問題可能會減緩市場的成長潛力。

銀屑病治療的獲得情況可能因地區而異。在服務不足的地區或醫療基礎設施有限的國家，患者可能難以獲得適當的護理，從而阻礙市場擴張。患者和醫療保健提供者缺乏對銀屑病的認知和教育可能會導致治療延遲或次優。努力提高認知和理解對於市場成長至關重要。

主要市場趨勢

生物療法占主導地位的治療方法：

全球銀屑病市場的一個顯著趨勢是生物療法的使用不斷增加。生物製劑是一種源自活生物體的藥物，針對牛皮癬涉及的特定免疫系統成分。與類固醇等傳統治療方法相比，它們在控制牛皮癬症狀方面表現出顯著的功效，而且副作用較少。因此，市場正在見證向生物療法的轉變，為患者提供更有效、更有針對性的治療選擇。

個人化醫療和精準治療：

個人化醫療在牛皮癬的治療中越來越受到關注。遺傳學和生物標記研究的進步使醫療保健提供者能夠根據個別患者的特定遺傳和分子特徵量身定做治療方案。這種趨勢允許更精確和有效的治療，最大限度地減少試錯方法並改善患者的治療結果。

遠距醫療和數位健康解決方案：

遠距醫療和數位健康解決方案在銀屑病市場的採用加速，尤其是在 COVID-19 大流行之後。患者現在可以更好地與皮膚科醫生和醫療保健提供者進行遠端諮詢。此外，數位工具和行動應用程式可以幫助患者追蹤他們的牛皮癬症狀和治療進度。這一趨勢增強了患者對銀屑病的參與、監測和整體管理，提高了護理品質和患者體驗。

這些趨勢反映了全球銀屑病市場正在朝著更有效、以患者為中心、技術先進的銀屑病管理方法不斷發展。它們標誌著銀屑病患者朝著更好的結果和改善的生活品質的積極轉變。

細分市場洞察

治療類型見解

根據治療類型，生物藥物細分市場將於 2022 年成為全球銀屑病藥物市場的主導者。生物藥物在全球銀屑病藥物市場中的主導地位可歸因於與其治療類型相關的幾個關鍵因素。生物藥物旨在針對在牛皮癬發展中發揮作用的免疫系統的特定組成部分。與皮質類固醇或外用乳膏等非生物治療相比，這種有針對性的方法可以帶來更高的治療效果和更有利的副作用。

生物藥物通常以較低的給藥頻率提供更持久的效果。有些生物製劑需要每隔幾週或幾個月注射或輸注，與每天或更頻繁地使用其他藥物相比，減輕了患者的治療負擔。生物製劑通常引起全身副作用的風險較低，因為它們專門作用於與牛皮癬有關的免疫系統成分。這與口服皮質類固醇等全身性治療形成鮮明對比，後者可能產生更廣泛且可能更嚴重的副作用。

生物藥物在減輕牛皮癬的身體和心理負擔方面顯示出顯著療效。患者的生活品質通常會顯著改善，包括搔癢、疼痛和發炎減少，以及皮膚外觀改善。這種對患者健康的正面影響推動了對生物製劑的需求。隨著患者對治療方案及其結果的了解越來越多，許多人由於生物製劑的有效性和安全性而表達了對生物製劑的偏好。這種患者偏好促成了生物藥物在市場上的主導地位。由於廣泛的臨床研究支持生物製劑的有效性和安全性，醫療保健提供者對處方生物製劑治療牛皮癬有了信心。醫生的這種信心進一步促進了生物製劑的使用。製藥公司在研發方面投入巨資，以創造和改進牛皮癬的生物療法。這種持續的創新導致了具有增強特性的新型生物製劑的開發，進一步鞏固了其在市場上的主導地位。預計這些因素將推動該領域的成長。

行動洞察機制

根據作用機制，白細胞介素抑制劑將在 2022 年成為全球銀屑病藥物市場的主導者。白細胞介素抑制劑專門針對參與銀屑病發展的免疫途徑。牛皮癬的特徵是免疫反應過度活躍，其中白細胞介素發揮至關重要的作用。透過抑制這些特定的白血球介素，例如 IL-17 和 IL-23，這些藥物可以有效地從根本上破壞疾病進程。白細胞介素抑制劑在臨床試驗中顯示出顯著的功效，通常可以快速改善牛皮癬症狀。開始治療後不久，患者常常會發現發炎、搔癢和皮膚損傷明顯減輕。

許多白細胞介素抑制劑的作用持續時間較長，因此可以減少給藥頻率。此類藥物中的一些藥物需要每隔幾週或幾個月注射或輸註一次，為患者提供便利性並提高依從性。白細胞介素抑制劑已顯示出能夠維持許多患者的病情緩解，並降低牛皮癬發作的風險。此功能對於尋求長期疾病控制的個人特別有價值。與口服皮質類固醇等全身性治療相比，白細胞介素抑制劑通常具有更有利的副作用。由於它們選擇性地作用於特定的白細胞介素，因此這些藥物引起廣泛的全身性副作用的風險較低。這些因素共同促進了該細分市場的成長。

給藥途徑

根據治療途徑，到 2022 年，局部治療將成為全球銀屑病藥物市場的主導者。局部治療直接應用於受影響的皮膚表面。這種非侵入性的給藥途徑不那麼令人恐懼，更容易被許多患者接受，特別是那些可能不願意使用注射或口服藥物的患者。

局部治療旨在局部作用於皮膚表面和皮下組織。它們直接針對皮膚中發生的發炎過程，這是牛皮癬的特徵。這種有針對性的行動最大限度地減少了系統暴露，降低了系統副作用的風險。局部治療有多種配方，包括乳膏、軟膏、凝膠、泡沫和噴霧。這種多功能性使醫療保健提供者能夠根據患者的個人喜好和不同銀屑病表現的具體需求量身定做治療選擇。局部治療對於輕度至中度牛皮癬病例特別有效，這些病例佔患者群體的很大一部分。他們為這些患者提供了實用且易於接受的治療選擇，而無需更具侵入性的治療。局部治療通常用作維持治療，以在更強化的治療（例如生物製劑或光療）獲得緩解後控制銀屑病症狀。當與其他治療結合使用時，它們還可以作為輔助治療，以提高整體療效。

區域洞察

2022年，北美成為全球銀屑病藥物市場的主導者，以價值計算，佔據最大的市場佔有率。該地區擁有先進的醫療基礎設施和完善的製藥業。這使得廣泛的研究和開發、新療法的快速採用以及各種牛皮癬藥物的可用性成為可能。北美很大一部分人口擁有健康保險，這有助於獲得牛皮癬治療，包括可能昂貴的生物製劑。北美國家處於銀屑病臨床研究的前沿，並進行了大量的臨床試驗和研究。這種研究驅動的環境有助於佔據市場主導地位。

亞太市場有望成為成長最快的市場，在預測期內為牛皮癬藥物參與者提供利潤豐厚的成長機會。亞太地區人口眾多，其中包括印度和中國等國家，牛皮癬盛行率不斷上升。該地區龐大的患者數量正在推動市場成長。隨著亞太國家醫療保健意識的提高，越來越多的患者因牛皮癬尋求醫療照護。這種趨勢可能會繼續增加對牛皮癬藥物的需求。中國和印度等國家經濟的快速成長導致中產階級不斷壯大，可支配收入也增加。這使得更多的人能夠負擔得起牛皮癬治療，包括生物製劑。亞太地區是製藥公司的新興市場。許多全球製藥公司正在擴大在該地區的業務，增加牛皮癬藥物的取得並推動市場成長。亞太地區的一些國家正在發起醫療保健計劃，以改善獲得優質醫療服務的機會，包括治療牛皮癬等慢性病。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和次要管理途徑
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球銀屑病藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依治療類型（生物藥物、小分子全身性藥物、熱帶療法）
  • 依作用機轉（TNF Alpha 抑制劑、PDE4 抑制劑、白血球介素抑制劑等）
  • 依給藥途徑（口服、腸外、局部）
  • 按地區
  • 按公司分類 (2022)
• 市場地圖

第 6 章：北美銀屑病藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 按作用機制
  • 依給藥途徑
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲銀屑病藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 按作用機制
  • 依給藥途徑
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區乾癬藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 按作用機制
  • 依給藥途徑
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲乾癬藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 按作用機制
  • 依給藥途徑
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲銀屑病藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按治療類型
  • 按作用機制
  • 依給藥途徑
• MEA：國家分析
  • 南非牛皮癬藥物
  • 沙烏地阿拉伯 牛皮癬藥物
  • 阿拉伯聯合大公國牛皮癬藥物

第 11 章：市場動態

• 促進因素與挑戰

第 12 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 13 章：全球銀屑病藥物市場：SWOT 分析

第14章：競爭格局

• 商業概覽
• 行動奉獻機制
• 最近的發展
• 主要人員
• SWOT分析
  • Biogen Idec
  • Boehringer Ingelheim
  • Celgene Corporation
  • Dr.Reddy`s Laboratories
  • Eli Lilly and Company
  • Forward Pharma
  • Johnson and Johnson (Janssen Biotech Inc.)
  • Leo Pharma AS
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.

第 15 章：策略建議

第 16 章：關於我們與免責聲明

In 2022, the Global Psoriasis Drugs Market achieved a valuation of USD 21.06 billion, and it is poised for substantial growth in the upcoming period, with a projected Compound Annual Growth Rate (CAGR) of 6.57% through 2028. The Global Psoriasis Drugs Market represents a dynamic and rapidly evolving sector within the pharmaceutical industry, primarily fueled by the escalating prevalence of psoriasis, advancements in treatment options, and a growing demand for more effective therapeutic interventions. This market overview offers insights into the present state and the key factors shaping the Global Psoriasis Drugs Market.

Psoriasis, a chronic autoimmune skin condition characterized by red, scaly patches on the skin, affects millions of individuals worldwide. The global incidence of psoriasis has been consistently on the rise, resulting in a significant patient population in need of effective treatment options. The condition not only presents physical symptoms but also has a substantial impact on the quality of life for affected individuals, underscoring the critical need for treatment. The landscape of psoriasis treatment has witnessed remarkable progress, encompassing a broad spectrum of therapeutic choices, including topical treatments (such as creams and ointments), phototherapy (light-based therapy), systemic treatments (oral medications), and biologic drugs. Biologics, which target specific components of the immune system, have gained prominence due to their superior efficacy and safety profiles.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 21.06 Billion
Market Size 2028	USD 30.79 Billion
CAGR 2023-2028	6.57%
Fastest Growing Segment	Oral
Largest Market	North America

Increasing Prevalence of Psoriasis

The increasing prevalence of psoriasis refers to the rising number of individuals worldwide who are diagnosed with this chronic autoimmune skin condition. Psoriasis is characterized by the rapid buildup of skin cells, leading to symptoms such as scaling, redness, and inflammation. Psoriasis has a genetic component, and individuals with a family history of the condition are more likely to develop it. As families expand and genetic information is passed down, the likelihood of psoriasis cases increases.

Environmental triggers, such as stress, smoking, and certain infections, can exacerbate psoriasis or trigger its onset. In our modern lifestyles, exposure to these triggers has become more common, contributing to the increasing prevalence. Changes in dietary habits, sedentary lifestyles, and increased exposure to pollution and urban environments may influence the development of psoriasis. These lifestyle factors can affect the immune system and skin health, potentially leading to psoriasis. Advances in medical knowledge and diagnostic techniques have led to better recognition and diagnosis of psoriasis cases. Healthcare providers are now more adept at identifying the condition, even in its milder forms, contributing to the apparent increase in prevalence.

Advancements in Research and Development

Research and development (R&D) efforts in the pharmaceutical industry have witnessed significant advancements, particularly in the field of dermatology and autoimmune diseases. These advancements include a deeper understanding of the molecular mechanisms underlying psoriasis, the discovery of novel drug targets, and the development of more targeted and effective therapies. Advancements in R&D are pivotal in driving market growth because they result in the creation of better psoriasis drugs. These innovations lead to drugs with improved efficacy, reduced side effects, and enhanced patient outcomes. The promise of innovative treatments encourages investment in the psoriasis drug market, attracting both pharmaceutical companies and investors.

Evolving Regulatory Environment

Regulatory bodies responsible for drug approvals have adapted to the changing healthcare landscape. They have recognized the urgent need for safe and effective psoriasis treatments. Consequently, the regulatory process for approving psoriasis drugs has become more efficient and accommodating. An evolving regulatory environment is crucial for market growth because it expedites the time it takes to bring new psoriasis drugs to market. Streamlined approvals mean that pharmaceutical companies can commercialize their products faster, allowing them to meet the demands of patients more promptly and stay competitive in the market.

Growing Patient Awareness

Patients today have greater access to information about psoriasis and its available treatments. This is primarily due to the internet, patient advocacy groups, and healthcare education initiatives. Patients are becoming more proactive in seeking treatment options and advocating for their healthcare needs. The increase in patient awareness is a significant driver of market growth because informed patients are more likely to seek medical help for their psoriasis. They actively engage with healthcare providers, leading to earlier diagnosis and treatment initiation. This trend not only benefits patients but also fuels the demand for psoriasis drugs.

Key Market Challenges

Limited Understanding of Psoriasis Causes and Triggers

Psoriasis is a multifactorial autoimmune disease, and its exact cause remains elusive. The complexity of its pathophysiology makes it challenging to develop targeted therapies. Psoriasis flare-ups can be triggered or exacerbated by various factors, including stress, infections, and lifestyle choices. Understanding and addressing these triggers on an individual basis is a complex task.

Genetic predisposition plays a role in psoriasis, but the genetic factors involved are diverse. Tailoring treatments to specific genetic profiles are a challenge that limits the development of personalized therapies.

High Research and Development Costs

Developing new psoriasis drugs requires extensive clinical trials to ensure safety and efficacy. These trials are costly and time-consuming, often taking several years to complete.

Meeting the stringent regulatory requirements for pharmaceuticals, including psoriasis treatments, involves substantial financial investments. This can deter smaller pharmaceutical companies from entering the market. The competitive nature of the pharmaceutical industry means that companies need to invest significantly in research and development to stay ahead. This high level of competition can be a barrier for smaller firms.

Access to Treatment and Healthcare Disparities

Some of the newer biologic therapies for psoriasis can be prohibitively expensive, limiting access for individuals without comprehensive insurance coverage. Affordability issues can slow down the market's growth potential.

Access to psoriasis treatment may vary significantly by region. In underserved areas or countries with limited healthcare infrastructure, patients may struggle to access appropriate care, hindering market expansion. Lack of awareness and education about psoriasis among patients and healthcare providers can result in delayed or suboptimal treatment. Efforts to increase awareness and understanding are essential for market growth.

Key Market Trends

Biologic Therapies Dominating Treatment Approaches:

One prominent trend in the Global Psoriasis Market is the increasing utilization of biologic therapies. Biologics are medications derived from living organisms and target specific immune system components involved in psoriasis. They have demonstrated remarkable efficacy in managing psoriasis symptoms with fewer side effects compared to traditional treatments like steroids. As a result, the market is witnessing a shift towards biologic therapies, offering patients more effective and targeted treatment options.

Personalized Medicine and Precision Therapies:

Personalized medicine is gaining traction in the treatment of psoriasis. Advances in genetics and biomarker research are enabling healthcare providers to tailor treatments to the specific genetic and molecular profiles of individual patients. This trend allows for more precise and effective therapies, minimizing trial-and-error approaches and improving patient outcomes.

Telemedicine and Digital Health Solutions:

The adoption of telemedicine and digital health solutions has accelerated in the psoriasis market, especially in the wake of the COVID-19 pandemic. Patients now have greater access to remote consultations with dermatologists and healthcare providers. Additionally, digital tools and mobile apps help patients track their psoriasis symptoms and treatment progress. This trend enhances patient engagement, monitoring, and overall management of psoriasis, improving the quality of care and patient experience.

These trends reflect the ongoing evolution of the Global Psoriasis Market towards more effective, patient-centered, and technologically advanced approaches to psoriasis management. They signify a positive shift towards better outcomes and improved quality of life for individuals living with psoriasis.

Segmental Insights

Type of Treatment Insights

Based on the type of treatment, the biologic drugs segment emerged as the dominant player in the global market for Psoriasis Drugs in 2022. The dominance of biologic drugs in the Global Psoriasis Drugs Market can be attributed to several key factors related to their type of treatment. Biologic drugs are designed to target specific components of the immune system that play a role in the development of psoriasis. This targeted approach results in higher treatment efficacy and a more favourable side effect profile compared to non-biologic treatments like corticosteroids or topical creams.

Biologic drugs often provide longer-lasting effects with less frequent dosing. Some biologics require injections or infusions every few weeks or months, reducing the burden of treatment for patients compared to daily or more frequent applications of other medications. Biologics typically have a lower risk of causing systemic side effects because they act specifically on the immune system components involved in psoriasis. This is in contrast to systemic treatments like oral corticosteroids, which can have broader and potentially more severe side effects.

Biologic drugs have shown significant efficacy in reducing the physical and psychological burdens of psoriasis. Patients often experience a substantial improvement in their quality of life, including reduced itching, pain, and inflammation, as well as improved skin appearance. This positive impact on patients' well-being drives the demand for biologics. As patients become more informed about treatment options and their outcomes, many express a preference for biologics due to their effectiveness and safety profile. This patient preference has contributed to the dominance of biologic drugs in the market. Healthcare providers have gained confidence in prescribing biologics for psoriasis treatment due to the extensive clinical research supporting their efficacy and safety. This confidence among physicians further promotes the use of biologics. Pharmaceutical companies have heavily invested in research and development to create and improve biologic therapies for psoriasis. This ongoing innovation has resulted in the development of new biologics with enhanced properties, further solidifying their dominance in the market. These factors are expected to drive the growth of this segment.

Mechanism of Action Insights

Based on the mechanism of action, the interleukin inhibitors segment emerged as the dominant player in the global market for Psoriasis Drugs in 2022. Interleukin inhibitors specifically target the immune pathways involved in the development of psoriasis. Psoriasis is characterized by an overactive immune response, with interleukins playing a crucial role. By inhibiting these specific interleukins, such as IL-17 and IL-23, these drugs effectively disrupt the disease process at its core. Interleukin inhibitors have demonstrated remarkable efficacy in clinical trials, often leading to rapid improvement in psoriasis symptoms. Patients frequently experience a significant reduction in inflammation, itching, and skin lesions shortly after starting treatment.

Many interleukin inhibitors have a prolonged duration of action, allowing for less frequent dosing. Some drugs in this category require injections or infusions every few weeks or months, offering convenience and improved adherence for patients. Interleukin inhibitors have shown the ability to maintain remission in many patients, reducing the risk of psoriasis flare-ups. This feature is particularly valuable for individuals seeking long-term disease control. Interleukin inhibitors generally have a more favorable side effect profile compared to systemic treatments like oral corticosteroids. Because they act selectively on specific interleukins, these drugs have a reduced risk of causing broad systemic side effects. These factors collectively contribute to the growth of this segment.

Route Of Administration

Based on the Route of Administration of treatment, the topical segment emerged as the dominant player in the global market for Psoriasis Drugs in 2022. Topical treatments are applied directly to the affected skin surface. This non-invasive route of administration is less intimidating and more acceptable to many patients, especially those who may be reluctant to use injections or oral medications.

Topical treatments are designed to act locally on the skin's surface and the underlying tissue. They directly target the inflammatory processes occurring in the skin, which are characteristic of psoriasis. This targeted action minimizes systemic exposure, reducing the risk of systemic side effects. Topical treatments come in various formulations, including creams, ointments, gels, foams, and sprays. This versatility allows healthcare providers to tailor treatment choices to individual patient preferences and the specific needs of different psoriasis manifestations. Topical treatments are particularly effective for mild to moderate psoriasis cases, which represent a significant portion of the patient population. They offer a practical and accessible treatment option for these patients without the need for more invasive therapies. Topical treatments are often used as maintenance therapy to keep psoriasis symptoms under control after more intensive treatments, such as biologics or phototherapy, have achieved remission. They can also serve as adjunct therapy when combined with other treatments to enhance overall effectiveness.

Regional Insights

North America emerged as the dominant player in the global Psoriasis Drugs market in 2022, holding the largest market share in terms of value. The region boasts advanced healthcare infrastructure and a well-established pharmaceutical industry. This allows for extensive research and development, rapid adoption of new treatments, and availability of a wide range of psoriasis drugs. A significant proportion of the population in North America has health insurance coverage, which facilitates access to psoriasis treatments, including biologics, which can be expensive. North American countries are at the forefront of clinical research in psoriasis, conducting numerous clinical trials and studies. This research-driven environment contributes to the dominance of the market.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Psoriasis Drugs players during the forecast period. Factors such The Asia-Pacific region has a massive population, including countries like India and China, where there is a rising prevalence of psoriasis. The sheer number of patients in this region is driving market growth. As healthcare awareness increases in Asia-Pacific countries, more patients are seeking medical attention for psoriasis. This trend is likely to continue to boost the demand for psoriasis drugs. Rapid economic growth in countries like China and India has led to an expanding middle class with greater disposable income. This enables more individuals to afford psoriasis treatments, including biologics. Asia-Pacific represents an emerging market for pharmaceutical companies. Many global pharmaceutical firms are expanding their presence in this region, increasing access to psoriasis drugs and driving market growth. Some countries in the Asia-Pacific region are launching healthcare initiatives to improve access to quality medical care, including treatments for chronic conditions like psoriasis.

Key Market Players

• Glanbia Plc

• Pfizer Inc.

• Bayer AG

• Amway Corp.

• GlaxoSmithKline plc.

• Good Health New Zealand

• The Nature's Bounty Co.

• NOW Foods

• Abbott

• Herbalife Nutrition

Report Scope:

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment:

• Biologic Drugs
• Small Molecule Systemic Drugs
• Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action:

• TNF Alpha Inhibitors
• PDE4 Inhibitors
• Interleukin Inhibitors
• Others

Psoriasis Drugs Market, By Route of Administration:

• Oral
• Parenteral
• Topical

Psoriasis Drugs Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations:

• Global Psoriasis Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Route of Administrations
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psoriasis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
  • 5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Market Map

6. North America Psoriasis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Treatment
  • 6.2.2. By Mechanism of Action
  • 6.2.3. By Route of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psoriasis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Treatment
      • 6.3.1.2.2. By Mechanism of Action
      • 6.3.1.2.3. By Route of Administration
  • 6.3.2. Canada Psoriasis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Treatment
      • 6.3.2.2.2. By Mechanism of Action
      • 6.3.2.2.3. By Route of Administration
  • 6.3.3. Mexico Psoriasis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Treatment
      • 6.3.3.2.2. By Mechanism of Action
      • 6.3.3.2.3. By Route of Administration

7. Europe Psoriasis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Treatment
  • 7.2.2. By Mechanism of Action
  • 7.2.3. By Route of Administration
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Psoriasis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Treatment
      • 7.3.1.2.2. By Mechanism of Action
      • 7.3.1.2.3. By Route of Administration
  • 7.3.2. United Kingdom Psoriasis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Treatment
      • 7.3.2.2.2. By Mechanism of Action
      • 7.3.2.2.3. By Route of Administration
  • 7.3.3. Italy Psoriasis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type of Treatment
      • 7.3.3.2.2. By Mechanism of Action
      • 7.3.3.2.3. By Route of Administration
  • 7.3.4. France Psoriasis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Treatment
      • 7.3.4.2.2. By Mechanism of Action
      • 7.3.4.2.3. By Route of Administration
  • 7.3.5. Spain Psoriasis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Treatment
      • 7.3.5.2.2. By Mechanism of Action
      • 7.3.5.2.3. By Route of Administration

8. Asia-Pacific Psoriasis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Treatment
  • 8.2.2. By Mechanism of Action
  • 8.2.3. By Route of Administration
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Psoriasis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Treatment
      • 8.3.1.2.2. By Mechanism of Action
      • 8.3.1.2.3. By Route of Administration
  • 8.3.2. India Psoriasis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Treatment
      • 8.3.2.2.2. By Mechanism of Action
      • 8.3.2.2.3. By Route of Administration
  • 8.3.3. Japan Psoriasis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Treatment
      • 8.3.3.2.2. By Mechanism of Action
      • 8.3.3.2.3. By Route of Administration
  • 8.3.4. South Korea Psoriasis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Treatment
      • 8.3.4.2.2. By Mechanism of Action
      • 8.3.4.2.3. By Route of Administration
  • 8.3.5. Australia Psoriasis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Treatment
      • 8.3.5.2.2. By Mechanism of Action
      • 8.3.5.2.3. By Route of Administration

9. South America Psoriasis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Treatment
  • 9.2.2. By Mechanism of Action
  • 9.2.3. By Route of Administration
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Psoriasis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Treatment
      • 9.3.1.2.2. By Mechanism of Action
      • 9.3.1.2.3. By Route of Administration
  • 9.3.2. Argentina Psoriasis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Treatment
      • 9.3.2.2.2. By Mechanism of Action
      • 9.3.2.2.3. By Route of Administration
  • 9.3.3. Colombia Psoriasis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Treatment
      • 9.3.3.2.2. By Mechanism of Action
      • 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Psoriasis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Treatment
  • 10.2.2. By Mechanism of Action
  • 10.2.3. By Route of Administration
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Psoriasis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Treatment
      • 10.3.1.2.2. By Mechanism of Action
      • 10.3.1.2.3. By Route of Administration
  • 10.3.2. Saudi Arabia Psoriasis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Treatment
      • 10.3.2.2.2. By Mechanism of Action
      • 10.3.2.2.3. By Route of Administration
  • 10.3.3. UAE Psoriasis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Treatment
      • 10.3.3.2.2. By Mechanism of Action
      • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

• 11.1. Drivers & Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Psoriasis Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Mechanism of Action Offerings
• 14.3. Recent Developments
• 14.4. Key Personnel
• 14.5. SWOT Analysis
  • 14.5.1. Biogen Idec
  • 14.5.2. Boehringer Ingelheim
  • 14.5.3. Celgene Corporation
  • 14.5.4. Dr.Reddy`s Laboratories
  • 14.5.5. Eli Lilly and Company
  • 14.5.6. Forward Pharma
  • 14.5.7. Johnson and Johnson (Janssen Biotech Inc.)
  • 14.5.8. Leo Pharma AS
  • 14.5.9. Merck and Co. Inc.
  • 14.5.10. Novartis AG
  • 14.5.11. Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer